We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Early Intervention Recommended for Certain Blood Clots

By HospiMedica International staff writers
Posted on 13 Aug 2008
New clinical guidelines for physicians that for the first time suggest the use of pharmacomechanical thrombolysis (PMT) for acute iliofemoral deep vein thrombosis (DVT) in conjunction with anticoagulation drug therapy.

The new American College of Chest Physicians (ACCP, Northbrook, IL, USA) venous thromboembolic (VTE) disease guidelines improve on the previous ACCP standard, which recommended the use of anticoagulation drug therapy alone for the treatment of DVT. More...
While anticoagulation alone mitigates the risk of clot propagation and pulmonary embolism, it often fails to clear the blockage. PMT, however, which consists of brief, high-pressure pulsed injections of a concentrated fibrinolytic agent to thrombus via a multi-sidehole catheter, has shown improved results in dissolving the DVT clot. The new guidelines appear in a supplement to the July 2008, issue of the journal Chest.

"This is a major change in the recommendations for the care of these patients with extensive DVT, and represents a major advance in treatment. Adopting an initial strategy of thrombus removal will improve the quality of life of these patients and potentially avoid recurrent DVT in the future,” said Anthony Comerota, M.D., director of the Jobst Vascular Center and adjunct professor of surgery at the University of Michigan (Ann Arbor, USA).

DVT can lead to serious consequences, including pulmonary embolism (PE) or post-thrombotic syndrome (PTS). DVT commonly affects the leg veins such as the femoral vein or the popliteal vein or the deep veins of the pelvis. Occasionally the veins of the arm are affected (known as Paget-Schrötter disease). The most common risk factors are recent surgery or hospitalization; 40% of these patients did not receive heparin prophylaxis. Other risk factors include advanced age, obesity, infection, immobilization, use of combined (estrogen-containing) forms of hormonal contraception, tobacco usage and air travel—known as economy class syndrome, a combination of immobility and relative dehydration--are some of the better-known causes.

Related Links:
American College of Chest Physicians
University of Michigan


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.